Mandate

Vinge advises industrifonden in connection with pharmalink’s capital raising of sek 96 million

October 08, 2013

Industrifonden and the Norwegian investment company, Investinor have invested a combined total of SEK 79 million in Pharmalink, the pharmaceuticals development company. Private investors have also contributed to the total capital raising of SEK 96 million. The funds will be used to further develop Pharmalink’s product portfolio.

Pharmalink is a pharmaceuticals company which improves and further develops existing pharmaceuticals. The company is currently conducting the Nefecon project for the treatment of inflammation of the kidneys and the Busulipo project for treatment prior to bone marrow transplantation.

Industrifonden has been a stakeholder in Pharmalink since 2004. The Norwegian investment company, Investinor is a new stakeholder.

Vinge partner Johan Larsson advised Industrifonden

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025